• Sizonqoba Study:  Providing ARV therapy to HIV-TB co-infected patients using a once daily ARV regime supervised by an existing community DOT program. Over 100 patients are followed up closely over a two year period where adverse events, adherence, TB and HIV outcomes are documented.

• Behavioural study: This study looks at behavior trends of patients as they improve on ARV therapy using an innovative interactive Audio-computer program. Patients are interviewed by a recorded questionnaire and respond by touching pictures on a computer screen. Totally illiterate patients are able to do this after a 15 min introduction.

• Natural History Study: This is a retrospective study following the natural course of HIV disease in 100 HIV/TB co-infected patients before the availability of HIV.

• Cost effective study: This is a comprehensive study of all cost implications of providing an ARV therapy rollout in a rural resource poor area.

• MDRTB surveillance: This surveillance looks at the prevalence of Multi-Drug resistant TB over time and documented an outbreak of an Extended Highly Drug Resistant form of TB in Msinga.

• Palliative Care Study: A qualitative study of palliative care provided by the various programs are documented, by patient, family and carer interviews.

• Andrews JR, Gandhi NR, Moll AP, Shah NS, Sturm AW, Lalloo U, Moodley P, Friedland G. Clinical Predictors of Multidrug and Extensively Drug-Resistant Tuberculosis in Tugela Ferry, South Africa. IUATLD (Cape Town), 2007. 

• Andrews JR, Gandhi NR, Moll AP, Shah NS, Sturm AW, Lalloo U, Moodley P, Friedland G. High Mortality Among Patients with Multidrug and Extensively Drug-Resistant Tuberculosis in Rural South Africa. IUATLD, Cape Town, 2007.

• Basu S, Andrews JR, Poolman ER, Gandhi NR, Shah NS, Moll A, Moodley P, Galvani AP, Friedland GH. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: a modeling study. Lancet 2007; 370: 1500-1507.

• Moll AP, Gandhi NR, Andrews JR, Sturm AW, Shah NS, Scott M, Lalloo U, Moodley P, Friedland G. Extensively Drug-Resistant (XDR) TB More Common than MDR TB in Tugela Ferry, South Africa with Evidence for Resistance Amplification Over Time. IUATLD, Cape Town, 2007.

• Moll, A. Treatment of HIV-associated XDR TB patients.  IUATLD, Cape Town, 2007. 

• Moodley P, Moll A, Shah NS, Gandhi N, Friedland G, Lalloo U G, Andrews J, Sturm AW. Multi- and extensively drug-resistant Mycobacterium tuberculosis in KwaZulu Natal. IUATLD, Cape Town, 2007. 

• Moodley P, Moll A, Shah NS, et al. Multi- and extensively drug-resistant Mycobacterium tuberculosis in KwaZulu Natal. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2007.

• Padayatchi N, Friedland G, Controlled decentralized management of multi- and extensively drug resistant TB: an alternative model of care.  IUATLD, Cape Town, 2007.

• Padayatchi N, Friedland G, Managing multiple and extensively drug-resistant tuberculosis and HIV. Expert Opin. Pharmacother. 8(8):1035-1037, 2007.

• Pillay M, Sturm AW. Evolution of the Extensively Drug-Resistant F15/LAM4/KZN Strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clinical Infectious Diseases 2007; 45:1409–14.

• Sturm AW. The role and value of molecular characterization of XDR-TB strains. IUATLD, Cape Town, 2007.

• Gandhi N, Moll A, Pawinski R, Zeller K, Lalloo U, Friedland G. Favorable outcomes of integration of TB and HIV treatment in a rural South Africa: the Sizonqoba study. Toronto: XVI International AIDS Conference, 2006 (abstr MOPE0181).

• Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet  2006; 368: 1575–80.   

External Site Links
This site contains links to other websites on the internet. While we provide links to them, we are not responsible for their content or privacy policies.